Results 161 to 170 of about 11,689 (208)

[Reactogenic and sensitizing properties of cholera vaccine].

Zhurnal mikrobiologii, epidemiologii i immunobiologii, 1971
openaire   +1 more source

Challenges and future perspectives of enhanced passive safety surveillance of influenza vaccines in Europe. [PDF]

Ther Adv Drug Saf
Amaral de Avila Machado M, Gandhi-Banga S, Serradell L, Gallo S, Wagué S, Moore TM, Khromava A.   +6 more
europepmc   +1 more source

From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine. [PDF]

Hum Vaccin Immunother
Straus W.
europepmc   +1 more source

Post-Acute Sequelae of COVID-19 at 12 Months in Hospitalized Patients: A Colombian Cohort Study. [PDF]

Cureus
Lora Mantilla AJ, Parra-Gómez LA, Ortegón-Vargas V, Posso Paz M, Cáceres Ramírez C, Vasquez-Cadena AJ, Ayala-Gutierrez MC, Amaya Muñoz MC, Blanco Rueda MP, Diaz Caraballo MI, Villabona-Florez SJ, Gomez Laitton ED, Camacho Lopez PA.   +12 more
europepmc   +1 more source

Comparison of Vaccine Adverse Events Between Zoster Vaccine Live and Recombinant Zoster Vaccine: A Prospective Multicenter Survey. [PDF]

J Korean Med Sci
Yoon JG, Nham E, Choi YJ, Choi WS, Choi MJ, Seo YB, Lee J, Hyun H, Heo JY, Noh JY, Song JY, Cheong HJ.   +11 more
europepmc   +1 more source

Identification of novel genetic biomarkers for ChAdOx1 nCoV-19 mediated immunogenicity. [PDF]

Front Immunol
Chou WH, Chang CM, Ting J, Lin MR, Liao HN, Chou YC, Wei CY, Chi HH, Ho SY, Luo WT, Tsai CL, Chao CH, Chen LC, Wu TH, Liu WC, Nguyen QA, Chang HW, Hung CS, Hong SY, Wang JC, Hsiao SH, Chang WC.   +21 more
europepmc   +1 more source

Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance. [PDF]

Drug Dev Res
Liao R, Luo M, Yang F, Xu L, Zhang J, Zhang W, Guan S, Zhang Y, Luo P, Cheng P, Yang J, Li Y, Wang Q.   +12 more
europepmc   +1 more source